Mr. James Howard-Tripp reports
STAGEZERO LIFE SCIENCES ANNOUNCES SECOND CLOSING OF CDN $3.7 MILLION PRIVATE PLACEMENT
Stagezero Life Sciences Ltd. has closed a $1,043,049 second tranche to complete the $3,708,000 private placement financing round as approved by shareholders at the company s annual and special meeting. The private placement is fully subscribed.
A total of 75 investors participated for total gross proceeds of $3,708,467. The private placement is structured as units at 11.5 cents and each unit includes one common share and one-half warrant, whereby each full warrant can be exercised for a period of 36 months at a price of 18.5 cents.
"We are already deploying the funds gained through the financing to expand our commercialization and the final validation of Aristotle," said James R. Howard-Tripp, chief executive officer of Stagezero. "The funding will also provide the company with the necessary finances to support the distribution agreements with additional telehealth partners and our new sales partner, Coastal Medical, as well as our collaboration with a large health care system."
About Stagezero Life Sciences Ltd.
Stagezero is dedicated to the early detection (stage 0) of cancer and multiple disease states through whole blood. Its next-generation test, Aristotle, is a multicancer panel for simultaneously screening 10 cancers from a single sample of blood with high-sensitivity and specificity for each cancer.
We seek Safe Harbor.
© 2019 Canjex Publishing Ltd. All rights reserved.